We assessed tumor cell characteristics associated with immune suppression (PD-L1, CD47, and HVEM) or known tumor features associated with response/resistance to daratumumab treatment (expression levels of CD38 and the complement inhibitory proteins CD55 and CD59). This evidence concerns the gene CD55 and neoplasm.